Lataa...
Study partners should be required in preclinical Alzheimer’s disease trials
BACKGROUND: In an effort to intervene earlier in Alzheimer’s disease (AD), clinical trials are testing promising candidate therapies in preclinical disease. Preclinical AD trial participants are cognitively normal, functionally independent, and autonomous decision-makers. Yet, like AD dementia trial...
Tallennettuna:
| Julkaisussa: | Alzheimers Res Ther |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5719524/ https://ncbi.nlm.nih.gov/pubmed/29212555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-017-0327-x |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|